AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Flunixin meglumine works by inhibiting the production of prostaglandins, which are inflammatory mediators involved in the body's response to injury or inflammation. By reducing prostaglandin levels, flunixin meglumine helps alleviate inflammation and associated symptoms.
Analgesic (Pain-Relieving) Effects: Flunixin meglumine has analgesic properties, meaning it helps relieve pain. It is often used to manage pain associated with various conditions, including musculoskeletal injuries, postoperative pain, colic in horses, and other painful inflammatory conditions in animals.
Fever Reduction: Flunixin meglumine can help reduce fever by inhibiting the production of prostaglandins, which play a role in regulating body temperature. It is commonly used to treat fever associated with infections or inflammatory conditions in animals.
Colic in Horses: Colic is a common and potentially life-threatening condition in horses characterized by abdominal pain. Flunixin meglumine is frequently used in horses to relieve pain and reduce inflammation associated with colic episodes.
Musculoskeletal Injuries: Flunixin meglumine is used to manage pain and inflammation associated with musculoskeletal injuries, such as strains, sprains, and arthritis, in various animal species.
Postoperative Pain Management: After surgical procedures, animals may experience pain and inflammation at the surgical site. Flunixin meglumine can be administered postoperatively to help alleviate pain and discomfort.
Dosage and Administration: The dosage and route of administration of flunixin meglumine vary depending on the species, the severity of the condition being treated, and the veterinarian's recommendation. It is typically administered by injection, either intravenously or intramuscularly.
Duration of Treatment: Flunixin meglumine is usually prescribed for short-term use to manage acute pain, inflammation, or fever in animals. The duration of treatment depends on the specific condition and the animal's response to therapy.
Side Effects: While generally safe when used as directed, flunixin meglumine can cause side effects in some animals, including gastrointestinal ulceration, renal toxicity, and reduced blood flow to the kidneys. Long-term or excessive use of flunixin meglumine may increase the risk of adverse effects.
Contraindications: Flunixin meglumine should not be used in animals with a known hypersensitivity to NSAIDs or a history of gastrointestinal ulceration. It should be used with caution in animals with preexisting renal or hepatic impairment.
Drug Interactions: Flunixin meglumine may interact with other medications, including other NSAIDs, corticosteroids, and drugs that affect renal function. Veterinarians should be aware of potential drug interactions and adjust treatment accordingly.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 4.7 | 0.2 | 22.5 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.5 | -0.67 |
| Allergic Rhinitis (Hay Fever) | 1 | 1.5 | -0.5 |
| Allergies | 4.3 | 1.4 | 2.07 |
| Allergy to milk products | 1 | 0.8 | 0.25 |
| Alopecia (Hair Loss) | 1.8 | 1.8 | |
| Alzheimer's disease | 2.4 | 3.3 | -0.38 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.6 | 3 |
| Ankylosing spondylitis | 2.7 | 0.8 | 2.38 |
| Anorexia Nervosa | 0.5 | 1.2 | -1.4 |
| Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
| Asthma | 0.3 | 0.7 | -1.33 |
| Atherosclerosis | 1 | 1.2 | -0.2 |
| Atrial fibrillation | 2.7 | 1.3 | 1.08 |
| Autism | 5.3 | 5.7 | -0.08 |
| Barrett esophagus cancer | 0.3 | 0.1 | 2 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 1.3 | 0.9 | 0.44 |
| Brain Trauma | 0.7 | 0.5 | 0.4 |
| Carcinoma | 3.1 | 2.9 | 0.07 |
| Celiac Disease | 2 | 3.5 | -0.75 |
| Cerebral Palsy | 0.8 | 1.1 | -0.38 |
| Chronic Fatigue Syndrome | 3.5 | 6.4 | -0.83 |
| Chronic Kidney Disease | 1 | 0.9 | 0.11 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.3 | 0.67 |
| Chronic Urticaria (Hives) | 0.7 | 0.9 | -0.29 |
| Coagulation / Micro clot triggering bacteria | 0.8 | 0.7 | 0.14 |
| Colorectal Cancer | 3.1 | 0.8 | 2.88 |
| Constipation | 1.1 | 0.3 | 2.67 |
| Coronary artery disease | 0.8 | 0.8 | 0 |
| COVID-19 | 10.1 | 10.5 | -0.04 |
| Crohn's Disease | 5.6 | 4.3 | 0.3 |
| cystic fibrosis | 0.2 | 0.8 | -3 |
| deep vein thrombosis | 0.2 | 0.4 | -1 |
| Depression | 7.4 | 6.3 | 0.17 |
| Dermatomyositis | 0.1 | 0.3 | -2 |
| Eczema | 0.4 | 1.2 | -2 |
| Endometriosis | 2.2 | 1.1 | 1 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.4 | 2.6 | -0.08 |
| Fibromyalgia | 2.2 | 2.1 | 0.05 |
| Functional constipation / chronic idiopathic constipation | 4.7 | 2.8 | 0.68 |
| gallstone disease (gsd) | 1.7 | 0.4 | 3.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 0.6 | 1.67 |
| Generalized anxiety disorder | 0.5 | 1.6 | -2.2 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.2 | -0.2 | |
| Graves' disease | 1.7 | 1 | 0.7 |
| Halitosis | 0.8 | 0.1 | 7 |
| Hashimoto's thyroiditis | 1.4 | 0.8 | 0.75 |
| Hidradenitis Suppurativa | 0.1 | 0.3 | -2 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | 0.3 | 6.33 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
| hyperglycemia | 0.1 | 1.7 | -16 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.4 | 1 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.2 | 3.9 | -0.77 |
| Hypothyroidism | 0.8 | -0.8 | |
| Hypoxia | 1 | 1 | |
| IgA nephropathy (IgAN) | 3.2 | -3.2 | |
| Inflammatory Bowel Disease | 2.5 | 5.9 | -1.36 |
| Insomnia | 0.8 | 0.6 | 0.33 |
| Intelligence | 1.2 | 1.2 | |
| Intracranial aneurysms | 1.5 | 0.4 | 2.75 |
| Irritable Bowel Syndrome | 3.7 | 4.2 | -0.14 |
| Liver Cirrhosis | 3.4 | 2.1 | 0.62 |
| Long COVID | 6.2 | 7.5 | -0.21 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 1 | 0.9 | 0.11 |
| ME/CFS with IBS | 0.1 | 2.2 | -21 |
| ME/CFS without IBS | 0.2 | 2.3 | -10.5 |
| Menopause | 2.2 | 2.2 | |
| Metabolic Syndrome | 6.3 | 6.9 | -0.1 |
| Mood Disorders | 9.3 | 6.3 | 0.48 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.3 | 0.33 |
| Multiple Sclerosis | 2.5 | 3.4 | -0.36 |
| Multiple system atrophy (MSA) | 0.6 | 0.8 | -0.33 |
| Neuropathy (all types) | 0.4 | 0.1 | 3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 4.1 | -2.73 |
| NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
| Obesity | 6.5 | 3.4 | 0.91 |
| obsessive-compulsive disorder | 6.8 | 2.2 | 2.09 |
| Osteoarthritis | 0.9 | 0.3 | 2 |
| Osteoporosis | 1.2 | 0.9 | 0.33 |
| pancreatic cancer | 0.6 | 0.6 | |
| Parkinson's Disease | 1.9 | 2.2 | -0.16 |
| Polycystic ovary syndrome | 2.1 | 1.6 | 0.31 |
| Postural orthostatic tachycardia syndrome | 0 | 0.5 | 0 |
| Premenstrual dysphoric disorder | 1 | 0.5 | 1 |
| primary biliary cholangitis | 0.2 | 1.3 | -5.5 |
| Psoriasis | 3.6 | 2.2 | 0.64 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.9 | 3.4 | 0.15 |
| Rosacea | 0.6 | 0.1 | 5 |
| Schizophrenia | 5.7 | 1.2 | 3.75 |
| scoliosis | 0.2 | 0.3 | -0.5 |
| Sjögren syndrome | 2.3 | 3.3 | -0.43 |
| Sleep Apnea | 1.1 | 1 | 0.1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.6 | -2 |
| Stress / posttraumatic stress disorder | 1.8 | 1.6 | 0.13 |
| Systemic Lupus Erythematosus | 3.1 | 1.4 | 1.21 |
| Tic Disorder | 1.3 | 1 | 0.3 |
| Tourette syndrome | 0.1 | 0.5 | -4 |
| Type 1 Diabetes | 4 | 1.4 | 1.86 |
| Type 2 Diabetes | 6.8 | 6.1 | 0.11 |
| Ulcerative colitis | 1.6 | 4.7 | -1.94 |
| Unhealthy Ageing | 3.4 | 1.3 | 1.62 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.